4.8 Article

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Journal

NATURE COMMUNICATIONS
Volume 10, Issue -, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41467-019-09745-2

Keywords

-

Funding

  1. Deutsche Forschungsgemeinschaft [SFB 1074, BU 1339/8-1]
  2. Else Kroner Fresenius Stiftung [2014_ A298]
  3. Thuringian state program ProExzellenz (RegenerAging) of the Thuringian Ministry for Research (TMWWDG) [FSU-I-03/14]

Ask authors/readers for more resources

Mutations in the nucleophosmin 1 (NPM1) gene are considered founder mutations in the pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of NPM1 mutated (NPM1(mut)) AML, we assess mutation status of five recurrently mutated oncogenes in 129 paired NPM1(mut) samples obtained at diagnosis and relapse. We find a substantial shift in the genetic pattern from diagnosis to relapse including NPM1(mut) loss (n = 11). To better understand these NPM1(mut) loss cases, we perform whole exome sequencing (WES) and RNA-Seq. At the time of relapse, NPM1(mut) loss patients (pts) feature distinct mutational patterns that share almost no somatic mutation with the corresponding diagnosis sample and impact different signaling pathways. In contrast, profiles of pts with persistent NPM1(mut) are reflected by a high overlap of mutations between diagnosis and relapse. Our findings confirm that relapse often originates from persistent leukemic clones, though NPM1(mut) loss cases suggest a second de novo or treatment-associated AML (tAML) as alternative cause of relapse.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma

Alexej Ballhausen, Amin Ben Hamza, Carlotta Welters, Kerstin Dietze, Lars Bullinger, Hans-Peter Rahn, Sylvia Hartmann, Martin-Leo Hansmann, Leo Hansmann

Summary: Lymph node-infiltrating T cells play a crucial role in classical Hodgkin lymphoma (cHL). Our study revealed the presence of clonally expanded T cells in the lymph nodes of untreated patients with cHL. These cells exhibited non-naive phenotypes and low expression of immune checkpoint molecules. These findings suggest that the therapeutic effects of immune checkpoint blockade may involve mechanisms beyond the dis-inhibition of pre-existing lymphoma-directed T cell responses.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Article Oncology

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients

Joanna Zaleska, Paulina Kwasnik, Magdalena Paziewska, Joanna Purkot, Aleksandra Szabelak, Mateusz Jurek, Natalia Masny, Izabela Dziatkiewicz, Bartosz Pronobis-Szczylik, Agnieszka Piebiak, Agnieszka Szymczyk, Katarzyna Jarosz-Chudzik, Lukasz Bolkun, Katarzyna Kozlowska, Jaroslaw Piszcz, Edyta Subocz, Janusz Halka, Michal Bator, Elzbieta Kalicinska, Tomasz Wrobel, Lidia Usnarska-Zubkiewicz, Justyna Rybka, Izabela Deren-Wagemann, Marta Szyca-Smieszniak, Jaroslaw Dybko, Iwona Hus, Bartosz Pula, Edyta Cichocka, Marcin Rymko, Dorota Zdunczyk, Mateusz Ziarkiewicz, Grzegorz Wladyslaw Basak, Lars Bullinger, Krzysztof Giannopoulos

Summary: Multiple myeloma and chronic lymphocytic leukemia patients have increased susceptibility to COVID-19 due to impaired immune function. This study evaluated the efficacy of mRNA COVID-19 vaccines in these patients and found that vaccination can induce specific CD8+ T cell responses, but they do not correlate positively with serological responses.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Hematology

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

Guus J. J. E. Heynen, Francis Baumgartner, Michael Heider, Upayan Patra, Maximilian Holz, Jan Braune, Melanie Kaiser, Isabell Schaeffer, Stefanos A. Bamopoulos, Evelyn Ramberger, Arunima Murgai, Yuen Lam Dora Ng, Uta Margareta Demel, Dominik Laue, Sven Liebig, Josefine Krueger, Martin Janz, Axel Nogai, Markus Schick, Philipp Mertins, Stefan Mueller, Florian Bassermann, Jan Kroenke, Ulrich Keller, Matthias Wirth

Summary: Proteasome inhibition is a highly effective treatment for multiple myeloma, but patients often develop resistance to proteasome inhibitors. Increased SUMOylation has been found in relapsed/refractory MM, and high expression of the SUMO E1-activating enzyme is associated with poor survival. Combination therapy with the SUMO E1-activating enzyme inhibitor and proteasome inhibitor showed synergy in MM cell lines and primary MM cells. Activated SUMOylation can be a therapeutic target for MM and combined SUMO/proteasome inhibition may be a potential strategy for treating proteasome inhibitor-resistant MM.

BLOOD ADVANCES (2023)

Article Hematology

Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

Piroska Klement, Walter Fiedler, Razif Gabdoulline, Louisa-Kristin Dallmann, Clara Philine Wienecke, Johannes Schiller, Christian Kandziora, Katrin Teich, Bennett Heida, Konstantin Buttner, Maximilian Brandes, Carolin Funke, Martin Wichmann, Basem Othman, Joerg Chromik, Stefanie Amberg, Maxim Kebenko, Vera Schlipfenbacher, Anne Christine Wilke, Franziska Modemann, Melanie Janning, Hubert Serve, Carsten Bokemeyer, Susann Theile, Ute Deppermann, Anne L. Kranich, Arnold Ganser, Felicitas Thol, Michael Heuser

Summary: Relapse is common in AML patients and has a poor prognosis. Treatment options are limited and understanding the molecular response patterns is challenging. In this study, we analyzed the response patterns of relapsed/refractory AML patients treated with selinexor and identified subclonal patterns. One patient showed a long-term course of remission with selinexor maintenance treatment after relapse following alloHCT. This exploratory study provides insights into the effects of selinexor in AML patients.

ANNALS OF HEMATOLOGY (2023)

Article Computer Science, Interdisciplinary Applications

Federated electronic data capture (fEDC): Architecture and prototype

Matthias Ganzinger, Max Blumenstock, Axel Fuerstberger, Leonard Greulich, Hans A. Kestler, Michael Marschollek, Christian Niklas, Tim Schneider, Cord Spreckelsen, Erik Tute, Julian Varghese, Martin Dugas

Summary: Structured documentation of findings is important in clinical research and patient care. Integration of electronic case report forms (eCRF) with electronic health records (EHR) is challenging when researchers from different institutions collaborate. To address this issue, a novel architecture for a federated electronic data capture system (fEDC) was proposed.

JOURNAL OF BIOMEDICAL INFORMATICS (2023)

Article Virology

Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TuSeRe:exact Study

Alan Bareiss, Gunalp Uzun, Marco Mikus, Matthias Becker, Karina Althaus, Nicole Schneiderhan-Marra, Axel Fuerstberger, Julian D. D. Schwab, Hans A. A. Kestler, Martin Holderried, Peter Martus, Katja Schenke-Layland, Tamam Bakchoul

Summary: This study investigates self-reported side effects after COVID-19 vaccination and finds that the frequency of local and systemic side effects differs significantly between mRNA and vector-based vaccines, and is associated with vaccine type, age, and gender.

VIRUSES-BASEL (2023)

Article Biochemistry & Molecular Biology

Accessing three-branched high-affinity cereblon ligands for molecular glue and protein degrader design

Robert Kuchta, Christopher Heim, Alexander Herrmann, Samuel Maiwald, Yuen Lam Dora Ng, Izidor Sosic, Tim Keuler, Jan Kroenke, Michael Guetschow, Marcus D. Hartmann, Christian Steinebach

Summary: In this study, the Petasis borono-Mannich reaction was used to synthesize three-branched cereblon ligands, which can interact with protein surfaces and have a suitable linker exit vector. The high-affinity ligands were used to create new molecular glues and PROTACs targeting BRD4 for degradation, providing insights into protein degraders and emphasizing the importance of multicomponent reactions (MCRs) in drug discovery.

RSC CHEMICAL BIOLOGY (2023)

Article Hematology

Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT

Alexandros Spyridonidis, Myriam Labopin, Bipin Savani, Sebastian Giebel, Gesine Bug, Stefan Schoenland, Nicolaus Kroeger, Matthias Stelljes, Thomas Schroeder, Andrew McDonald, Igor-Wolfgang Blau, Martin Bornhaeuser, Montse Rovira, Wolfgang Bethge, Andreas Neubauer, Arnold Ganser, Jean Henri Bourhis, Matthias Edinger, Bruno Lioure, Gerald Wulf, Kerstin Schaefer-Eckart, Mutlu Arat, Zinaida Peric, Christoph Schmid, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty

Summary: In this registry-based study, the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) in adult patients with acute lymphoblastic leukemia (ALL) were compared. The study found that the total dose of total body irradiation (TBI) did not influence the survival outcomes for patients, regardless of whether they received a standard 12-Gray or lower 8-Gray dose.

HEMASPHERE (2023)

Article Oncology

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

Claudia M. Denkinger, Maike Janssen, Ulrike Schaekel, Julia Gall, Albrecht Leo, Patrick Stelmach, Stefan F. Weber, Johannes Krisam, Lukas Baumann, Jacek Stermann, Uta Merle, Markus A. Weigand, Christian Nusshag, Lars Bullinger, Jens-Florian Schrezenmeier, Martin Bornhaeuser, Nael Alakel, Oliver Witzke, Timo Wolf, Maria J. G. T. Vehreschild, Stefan Schmiedel, Marylyn M. Addo, Felix Herth, Michael Kreuter, Phil-Robin Tepasse, Bernd Hertenstein, Mathias Haenel, Anke Morgner, Michael Kiehl, Olaf Hopfer, Mohammad-Amen Wattad, Carl C. Schimanski, Cihan Celik, Thorsten Pohle, Matthias Ruhe, Winfried Kern, Anita Schmitt, Hanns-Martin Lorenz, Margarida Souto-Carneiro, Mary Gaeddert, Niels Halama, Stefan Meuer, Hans-Georg Kraeusslich, Barbara Mueller, Paul Schnitzler, Sylvia Parthe, Ralf Bartenschlager, Martina Gronkowski, Jennifer Klemmer, Michael Schmitt, Peter Dreger, Katharina Kriegsmann, Richard F. Schlenk, Carsten Muller-Tidow

Summary: Patients with cancer and compromised immune systems may benefit from convalescent/vaccinated plasma treatment to improve COVID-19 outcomes.

NATURE CANCER (2023)

Review Oncology

Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany

Andreas Schmidt, Christiane Bernhardt, Dieter Buerkle, Stefan Fries, Carla V. Hannig, Kathleen Jentsch-Ullrich, Andreas Josting, Stephan Kreher, Marcel Reiser, Hans Tilman Steinmetz, Hans Tesch, Stephanie Terner, Alexander Schulte, Carl C. Crodel, Francesca Palandri, Florian H. Heidel

Summary: This study evaluated the real-life approach to clinical characteristics, diagnostic assessment, risk stratification, and treatment decisions for MPN patients classified as ET or MF after the implementation of the WHO 2016 classification. It was found that some patients diagnosed with ET did not undergo bone marrow testing, and some patients diagnosed with MF did not receive early prognostic risk assessment. Improved histopathologic diagnostics and dynamic risk stratification are recommended for precise risk assessment and therapeutic stratification.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Hematology

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial

Hartmut Doehner, Daniela Weber, Julia Krzykalla, Walter Fiedler, Michael W. M. Kuehn, Thomas Schroeder, Karin Mayer, Michael Luebbert, Mohammed Wattad, Katharina Goetze, Lars Fransecky, Elisabeth Koller, Gerald Wulf, Jan Schleicher, Mark Ringhoffer, Richard Greil, Bernd Hertenstein, Juergen Krauter, Uwe M. Martens, David Nachbaur, Maisun Abu Samra, Sigrid Machherndl-Spandl, Nadezda Basara, Claudia Leis, Anika Schrade, Silke Kapp-Schwoerer, Sibylle Cocciardi, Lars Bullinger, Felicitas Thol, Michael Heuser, Peter Paschka, Verena I. Gaidzik, Maral Saadati, Axel Benner, Richard F. Schlenk, Konstanze Doehner, Arnold Ganser

Summary: This study aimed to evaluate the efficacy of intensive chemotherapy with the anti-CD33 antibody-drug conjugate gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia. The results showed that gemtuzumab ozogamicin significantly reduced the cumulative incidence of relapse, suggesting that it may reduce the need for salvage therapy in these patients.

LANCET HAEMATOLOGY (2023)

Article Oncology

Sarcoma Patients Admitted to the Intensive Care Unit (ICU): Predictive Relevance of Common Sepsis and Performance Parameters

Jana K. Striefler, Phung T. Binder, Franziska Brandes, Daniel Rau, Silvan Wittenberg, David Kaul, Siyer Roohani, Armin Jarosch, Frederik M. Schaefer, Robert Oellinger, Sven Maerdian, Lars Bullinger, Kai -Uwe Eckardt, Jan Kruse, Anne Floercken

Summary: This study retrospectively analyzed sarcoma patients admitted to the ICU from 2005 to 2022. Sex, tumor localization, therapeutic intention, line of chemotherapy, SAPS II score, and SOFA score significantly impacted overall survival. The study confirms the predictive relevance of established sepsis and performance scores in sarcoma patients.

CANCER MANAGEMENT AND RESEARCH (2023)

Article Multidisciplinary Sciences

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

Kai Rejeski, Ariel Perez, Gloria Iacoboni, Viktoria Blumenberg, Veit L. Buecklein, Simon Voelkl, Olaf Penack, Omar Albanyan, Sophia Stock, Fabian Mueller, Philipp Karschnia, Agnese Petrera, Kayla Reid, Rawan Faramand, Marco L. Davila, Karnav Modi, Erin A. Dean, Christina Bachmeier, Michael von Bergwelt-Baildon, Frederick L. Locke, Wolfgang Bethge, Lars Bullinger, Andreas Mackensen, Pere Barba, Michael D. Jain, Marion Subklewe

Summary: Study reveals that intermittent neutrophil recovery after CAR-T cell therapy is associated with better survival outcomes, while aplastic recovery is associated with unfavorable expansion and tumor burden. Serum proteomics analysis shows that prolonged neutrophil aplasia occurs in patients with baseline systemic immune dysregulation, characterized by markers of endothelial dysfunction, increased inflammatory cytokines, macrophage activation, and T cell suppression. The association between neutrophil recovery and survival outcomes highlights critical interactions between host hematopoiesis and the immune state stimulated by CAR-T infusion.

SCIENCE ADVANCES (2023)

Article Cell Biology

Ribosomal Dysfunction Is a Common Pathomechanism in Different Forms of Trichothiodystrophy

Gaojie Zhu, Fatima Khalid, Danhui Zhang, Zhouli Cao, Pallab Maity, Hans A. Kestler, Donata Orioli, Karin Scharffetter-Kochanek, Sebastian Iben

Summary: Mutations in various genes can cause the childhood disorder TTD, which is classified as a DNA repair disease or a transcription syndrome. Knockout/knockdown of TTDN1 and RNF113A resulted in consistent effects on ribosomal biogenesis and performance. Interference with these TTD factors led to downregulation of RNA polymerase I transcription, disrupted rRNA processing, reduced rRNA 18S backbone, impaired protein translation decoding, and accumulation of misfolded and carbonylated proteins, suggesting loss of protein homeostasis. This study proposes that ribosomal dysfunction is a common underlying mechanism in TTD.

CELLS (2023)

Article Oncology

Primary myelofibrosis Diagnosis, clinical presentation and treatment options

Florian H. Heidel, Carl C. Crodel, Hans H. Kreipe

Summary: This review focuses on primary myelofibrosis (PMF) and provides an overview of diagnostic criteria, clinical presentation, and therapeutic options. Diagnostic criteria include histopathologic characteristics, molecular evidence, and exclusion of other myeloid neoplasms. Treatment strategies are based on risk of progression and symptom burden, including allogeneic stem cell transplantation and JAK inhibitors.

ONKOLOGIE (2023)

No Data Available